Media stories about Utah Medical Products (NASDAQ:UTMD) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Utah Medical Products earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news headlines about the medical instruments supplier an impact score of 45.7511027481739 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Separately, BidaskClub raised Utah Medical Products from a “hold” rating to a “buy” rating in a research note on Wednesday, December 6th.
Utah Medical Products (UTMD) opened at $91.35 on Wednesday. The company has a market capitalization of $348.62, a price-to-earnings ratio of 39.89 and a beta of 0.77. Utah Medical Products has a fifty-two week low of $58.50 and a fifty-two week high of $94.65.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 3rd. Shareholders of record on Friday, March 16th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $1.08 annualized dividend and a yield of 1.18%. Utah Medical Products’s payout ratio is currently 47.16%.
In other Utah Medical Products news, Director Ernst G. Hoyer sold 1,529 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $88.08, for a total transaction of $134,674.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ernst G. Hoyer sold 5,212 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $89.11, for a total value of $464,441.32. Following the transaction, the director now owns 28,838 shares in the company, valued at $2,569,754.18. The disclosure for this sale can be found here. Insiders have sold a total of 15,069 shares of company stock worth $1,363,536 over the last 90 days. 8.80% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/03/14/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-utah-medical-products-utmd-stock-price/1923596.html.
Utah Medical Products Company Profile
Utah Medical Products, Inc (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company’s product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts.
Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.